Publications by authors named "J D Puglisi"
Glucagon-like peptide-1 agonists (GLP-1 RAs) have produced substantial weight loss effects in type 2 diabetes mellitus (T2DM) cohorts, but these effects have not been thoroughly studied in patients with obesity and without diabetes. This review aimed to analyze direct comparative studies for semaglutide versus other GLP-1 RA (liraglutide and efinopegdutide) in facilitating weight loss and evaluating adverse events in patients with obesity. A systematic search following the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed in PubMed, Embase, and Cochrane Library for direct comparative studies comparing semaglutide with other GLP-1 RA on weight loss in patients with obesity.
View Article and Find Full Text PDFIntroduction: Previous evidence indicates that gestational hypoxia disrupts cerebrovascular development, increasing the risk of intracranial hemorrhage and stroke in the newborn. Due to the role of cytosolic Ca in regulating vascular smooth muscle (VSM) tone and fetal cerebrovascular blood flow, understanding Ca signals can offer insight into the pathophysiological disruptions taking place in hypoxia-related perinatal cerebrovascular disease. This study aimed to determine the extent to which gestational hypoxia disrupts local Ca sparks and whole-cell Ca signals and coupling with BK channel activity.
View Article and Find Full Text PDFArticle Synopsis
- Low energy availability (LEA) happens when athletes burn more calories than they consume, leading to decreased performance and higher injury risks, particularly affecting those in endurance and weight-class sports.
- The study aimed to find out how common LEA and relative energy deficiency in sport (REDs) are among athletes and analyze their impact on performance and injuries.
- Out of 59 studies reviewed, about 44.7% of athletes were found to have LEA, with specific decreases in performance and some mixed conclusions on the direct link to injury risks.
Article Synopsis
- - Obesity is linked to serious health issues like diabetes and cardiovascular disease, and GLP-1 receptor agonists (GLP-1 RAs) help in weight loss for individuals with diabetes.
- - This systematic review compared the weight loss effects of semaglutide against other GLP-1 RAs, revealing that semaglutide resulted in greater weight loss than liraglutide and dulaglutide but was outperformed by tirzepatide.
- - Analysis of the included studies (5,445 patients) showed average weight loss of various GLP-1 RAs, with common minor gastrointestinal side effects; however, the lack of thorough head-to-head trials limits conclusive comparisons.